India's Jubilant Pharmova reported a surge in its fourth-quarter adjusted profit on Friday, driven by strong demand for its drugs with radioactive ingredients, used to treat cancer and other diseases.

U.S.-based Waters Corp , which makes medical equipment used in clinical testing, has seen a spurt in demand from drugmakers ...

Trademark Dispute In The Pharmaceutical Industry. Legal News and Analysis - India - Dispute Resolution, Intellectual Property ...

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...

The medicine, Trastuzumab deruxtecan, was already available for some breast and stomach cancers. It has been approved to ...

BioZen Limited, a clinical-stage biotech company focussed on developing innovative treatments for endocrine disorders, today announced that the United Kingdom Patent Office has granted a new patent ...

India, a rapidly developing economy ... This calculation provides insight into the company's value. In other words, market valuation measures a company's size and success. It's a key factor ...

Other than that, nothing,” says the 69-year-old chairman and managing director of Sun Pharma, India’s largest pharmaceutical company ... for advanced skin cancer—a high-value therapy.

Ajanta Pharma has reported its Q4 numbers for fiscal year 2024–25. The company recorded a consolidated net profit of ₹225 crore in the March 2025 quarter. It is up by 11% from ₹203 crore in ...